More on LLY
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1240.34 |
|
|||
| Open | $1240.34 | ||||
| 52 Wk High | $88.16 | ||||
| 52 Wk Low | $67.88 | ||||
| Day High | $1240.34 | ||||
| Day Low | $1240.34 | ||||
| P/E | 287.12 | ||||
| EPS | $4.32 | ||||
| Volume | 3,683 | ||||
- Form SCHEDULE 13G/A ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
- Lilly's Omvoh meets primary endpoint in pediatric colitis trial
- Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
- Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
- Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- Lilly's Omvoh shows composite disease control in bowel disease trials
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep re
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Eli Lilly shares gain 3.3% on pipeline news, analyst upgrades
Entities mentioned with LLY
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Maynard Um | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- Dividend | View Related Stories »
- Show More...
